Wednesday, 8 July 2020

Hepatitis C Drugs Market, Segments, Growth And Value Chain Analysis 2019

Market Synopsis of Global Hepatitis C Drugs Market:
Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay colored stools etc.
Hepatitis is caused by a variety of factors both microbial and non-microbial. However hepatitis C is caused by hepatitis C virus and affects between 130–150 million people globally every year of which approximately 700 000 people die from hepatitis C-related liver diseases. What is of greater concern is the fact that 15 to 20% of chronically infected patients develop liver cirrhosis or liver cancer.
The market for hepatitis C is driven by factors such as disease prevalence, rise in government subsidy and reimbursement especially in U.S., greater screening especially in developing nations, drug abuse and unsafe sex etc.
However the restraints are overwhelming such as self-imitating nature of the disease in a sizable number of patients, challenge of herbal treatment offered at negligible prices especially in developing regions, price war between companies such as between Gilead and Merck, rising urbanization and better sanitation etc. Thus the market in developed regions appears to reach a plateau as the number of people affected is not rising in developed regions. The reevaluation of hepatitis C strategy by companies such as Boehringer Ingelheim and its decision to refrain from moving forward in hepatitis C research also is an indication of stagnancy in developed region markets.
The market is also unitary with a few dominant players such as Gilead with a few brands such as Sovaldi, Harvoni etc are leading the market. The development pipeline is however strong in the vaccine segment and it is expected that a vaccine will make its foray in the near future as happened with other forms of hepatitis.
Taking into consideration all factors the market for global hepatitis drugs was estimated to rise from $18700 million to $22721.1 million by the end of forecasting period reflecting a sluggish CAGR of 3.3%.
Study Objectives Global Hepatitis C Drugs Market:
  • To provide detail analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global Hepatitis C drugs market
  • To provide insights about factors affecting the market growth
  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future prospective
  • To provide country level analysis of the market for segments by drug class (anti-viral, immuno-modulators and others), by medicine system (allopathic, alternative and others), by route of administration (oral, injectable and others) and by end user (hospitals and private)
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.
Key Players for Global Hepatitis C Drugs Market:
Some of the key players in this market are: Gilead sciences Inc., Abbvie Inc, Johnson & Johnson, Merck & co. Inc., Glaxosmithkline plc, Novartis AG, Bristol-Myers Squibb, Hoffmann-la Roche ltd. and others.
Segments:
Global hepatitis c drugs market has been segmented on the basis of drug class which comprises anti-viral, immuno-modulators and others. On the basis of medicine system; market is segmented into allopathic, alternative and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of end user the market is segmented into hospitals and private.
Regional Analysis of Global Hepatitis C Drugs Market:
Globally America is the largest market for Hepatitis C drugs. Europe is the second-largest market for Hepatitis C drugs. The developed regions market is expected to remain stagnant and even may show negative CAGR due to falling patient’s number. Thus market of developing nations however will show moderate growth and is expected to catch on the developed regions. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global hepatitis C market.
The report for Global Hepatitis C Drugs Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Microspheres Market 2019 - Opportunity, Driving Trends And Deep Study 2023

Global Microspheres Market – Overview
Microspheres are characteristically free flowing powders having a particle size less than 200 µm. The microspheres used are usually polymers that are classified into two material type the first one is the natural polymers and the other one is the synthetic polymers. These microspheres are used in various industries such as pharmaceutical industry, construction industry, cosmetics industry, oil & gas industry and automotive industry.
The global Microspheres market is growing with the prompt pace. The market is forecast to establish a significant growth by 2022, beyond its previous growth records in terms of value with a striking CAGR of 11.9% during the anticipated period (2017 – 2022). The global microspheres market is growing at a rapid pace. The growth of the market is majorly upsurged by various applications and advancements of microspheres in a controlled delivery system. The various application such as carriers for drugs, absorption, and desorption of substances, pulmonary drug delivery, and tissue regeneration are influencing the growth of microspheres in the field of pharmaceutical industry. Furthermore, development in new drugs, government funding in research and development of microspheres and various others applications of microspheres in the field of construction industry, cosmetics industry, oil & gas industry and automotive industry are further enhancing the market for microspheres. As there is a wide range of factors that are driving the growth of the market, there are few barriers as well that hamper the market for microspheres. One of the factors that hamper the growth of the market are fluctuating price of raw materials, huge investment in R&D and the limitation of microspheres such as, the release rate of dose may vary from one dose to another.
Global Microspheres market - Competitive Analysis
The market for microspheres is characterized by the presence of several well-established and small players, the global market for microspheres appears to be highly competitive and fragmented. Major players are increasingly expanding their footprint in the emerging nations, making it putting pressure on the regional players, especially in terms of features such as type, product portfolios, and pricing. To attract the customers the companies have launched the products of different materials and in different sizes. Some companies have adopted the strategy of acquisition and collaboration to expand their market and minimize the competition. Innovation is the best way to gain the market, thus, a number of companies are involved in the development of new and better products.
For instance, in January 2017, Telko has established a new partnership with Potters to supply performance solid and hollow microspheres for a variety of applications. This partnership can help both Potters and Sovitec to deal a more widespread, cost-effective and high-quality portfolio of products and services to the customers worldwide.
3M (Unites States), Potters Industries LLC (United States), AkzoNobel N.V. (Netherlands), Momentive Performance Materials Inc. (United States), Chase Corporation (United States), Matsumoto Yushi Seiyaku Company (Japan), Sigmund Lindner GmbH (Germany), Mo-Sci Corporation (United States), Trelleborg AB (Sweden), Luminex Corporation (United States) and others are some of the prominent players at the forefront of competition in the global Microspheres market and are profiled in MRFR Analysis. 
Global Microspheres market   - Regional Analysis
Globally, North America holds the largest share of more than 44% of global microspheres market and is expected to be the leading market during 2016-2022. This large share is majorly attributed due to growing technology advancement in the field of medical science in the region, rapidly growing pharmaceutical industry, increasing need for the new formulations for the development of new drugs, some of the key factors driving the growth of this market.
Globally Europe holds the second largest share of about 31% of the global microspheres market.  The European market is expected to reach USD 2.44 billion by the end of the forecasted period from 2016 to 2022. Asia-Pacific region is anticipated to observe the highest growth rate in the near future due to growing healthcare and life-sciences industry, increased adoption of microspheres in developing countries, are the key drivers that are influencing the market to grow at a rapid pace in this region. Furthermore, major players are grabbing the opportunity by expanding their operating sites in the region and thus increasing the growth of this market for the forecasted period from 2016 to 2022.

Biomarkers Market Up To 2027: Top Companies, Growth Factors Details And Regional Overview By Types & Application

Market Synopsis of Biomarkers Market:
Global Biomarkers Market is expected to register a CAGR of 10.28% during the assessment period of 2020 to 2027, to reach USD 4,582.8 Million by 2027.
With an increasing incidence rate of chronic and life-threatening diseases, the demand for precise diagnostic procedures is increasing. In addition to that, there is an increase in the number of manufacturers, distributors, and service providers of biomarkers across the globe, creating enormous growth opportunities in the market.
Market Dynamics
The use of biomarkers in oncology has been extensive than any other disease for more than three decades. Biomarkers have found its use beyond the research laboratory to more clinical use as in the diagnosis, monitoring of disease status, and treatment efficacy. Hence, the rising cases of cancer are likely to drive the market for biomarkers globally. According to the World Cancer Research Fund International, globally, about one in six deaths are found due to cancer. The National Cancer Institute stated that in 2018, around 1,735,350 new cases of cancer were diagnosed in the US, and 609,640 people died from the disease.
Additionally, according to the International Agency for Research on Cancer, over 4,229,662 cases of cancer were detected in Europe in 2018. Moreover, according to the Cancer Council, cancer is a leading cause of death in Australia, and over 145,000 new cases of cancer were diagnosed in Australia in 2019, and the number is set to rise to 150,000 by 2020. This huge number of cancer cases is expected to drive the market for biomarkers as they help in the diagnosis and treatment of cancer.
Segmentation
The Global Biomarkers Market is segmented Based on Product, Type, Application, and Disease Indication.
The Biomarkers Market, based on product, has been segmented into consumables, services, and software. The rising applications of biomarkers in neurology and oncology, customization of reagents and kits provided by the manufacturers, and improved sensitivity and refined specificity are some of the factors garnering revenue for key players available in the global biomarkers market. The reproducibility of an immunoassay proves to be a cost-effective aspect for the validation of biomarkers while working on long-term research.
The biomarkers market, based on type, has been segmented into safety biomarkers, efficacy biomarkers, and validation biomarkers. The efficacy biomarkers are further segmented into predictive, surrogate, pharmacodynamics, and prognostic biomarkers. The safety biomarkers held the largest revenue in 2019, while the efficacy biomarkers segment registered the highest CAGR during the forecast period. Technological advancements in sequence profiling tools, multiplex biomarkers platform, and increasing need to interpret sequences of DNA, proteins, and nucleic acids are increasing the testing through biomarkers.
The global biomarkers market, by application, has been segmented into diagnostics, drug discovery and development, personalized medicine, disease risk assessment, and others. The increasing incidence and prevalence rates of chronic diseases, surge in the companies operating in the market, an increasing number of clinical trial candidates, and the need for precise therapy and diagnosis are pushing the growth of the application segment. The others segment includes DNA fingerprinting, forensics, and ecotoxicology.
The global biomarkers market, by disease indication, has been segmented into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and others. The segment growth can be attributed to the ability of biomarkers to cover clinical needs from cancer to infectious disease applications. Additionally, factors such as the rising incidence of various life-threatening diseases and rising geriatric population around the globe are indirectly propelling market growth.
Regional Analysis
The Global Biomarkers Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The Americas held the largest market share for biomarkers in 2019. This share is attributed to increasing developments in diagnostic applications of biomarkers, spurring R&D funding for biomarker research, and high prevalence of cancer.  
The European biomarkers market has been divided into Western Europe and Eastern Europe. The Western Europe biomarkers market has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. Europe accounts for the second-largest share in the global biomarkers market. Europe would follow the Americas in terms of market value during the forecast period owing to the presence of favorable government initiatives and laws, large target population base, rising prevalence of lifestyle-associated conditions, and increasing adoption rate of biomarker dependent diagnostic tests.
The biomarkers market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the rest of Asia-Pacific. Asia-Pacific is expected to witness the highest market growth potential over the forecast period due to the increasing number of contract research organizations and the low cost of clinical trials coupled with the growing adoption of advanced medical imaging systems.  
The Middle East & Africa biomarkers market is segmented into two major regions, namely the Middle East and Africa. In this region, the Middle East would hold a substantial market share over the assessment period due to developing healthcare infrastructure, and gradually increasing adoption of treatment.
Key Players
The Prominent Players in the Global Biomarkers Market are Qiagen N.V., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Merck KGaA, Bio-Rad Laboratories, Abbott Laboratories, EKF Diagnostics, Enzo Biochem Inc., Meso Scale Diagnostics, LLC, Signosis, and PerkinElmer Inc. and others.
Some of the key strategies followed by players operating in the global biomarkers market were product launches & licensing, mergers & acquisitions, expansions, and joint ventures among others.
  • In March 2020, F. Hoffmann-La Roche Ltd announced the approval by the US Food and Drug Administration (FDA) for its CINtec PLUS Cytology as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus (HPV) using the cobas 4800 HPV Test
  • In November 2019, Merck and Personalis, a cancer genomics company, entered into a partnership to identify and develop novel clinical biomarkers for cancer therapies. Under the terms of the partnership, Merck plans to use Personalis’ newest cancer immunogenomics platform ImmunoID NeXT for clinical biomarker identification and development

Digital Pathology Market To Observe Strong Development By 2019

Global Digital Pathology Market   - Overview
With the evolution of information technology in the past few years, a rapid change has being observed in the practice of pathology. Various novel techniques have been implemented, primarily in the form of digital imaging and Telepathology (TP). Digital pathology is a branch which can be defined as the electronic capture, management, analysis and distribution of gross or microscopic specimens. It encompasses the use of digital imaging as well as TP. Digital pathology has a wide spectrum of applications that includes primary diagnosis, intraoperative diagnosis, consultation, quality assurance, archiving, research and academic studies. This technique helps in speeding up the process of diagnosis and further treatment. It also helps in research procedures by offering an easy access to the previously stored digital information. As per the Royal College of Pathologists, in the UK alone pathologists carry out 121,000 autopsies each year which has supported the market growth.
The global digital pathology market size is growing with the rapid pace; mainly due technologically advanced diagnostic tools for the chronic diseases such as cancer has upsurged the demand for digital pathology. According to a recent study report published by the Market Research Future, The global digital pathology market is booming and expected to gain prominence over the forecast period growing rapidly. The market is forecasted to demonstrate a spectacular growth by 2022, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2022).
Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1955 
The market is expected grow with the same trends during the forecast period. The major drivers will be rapid technological advancements in digital pathology system such as advancements in digital imaging, robotic light microscopy, and multiple fiber optic communications among others. Moreover, growing prevalence of chronic conditions, that has expected to uplift the demand for digital pathology in order to improve existing patient diagnostic imaging measures and reduce high cost associated with the traditional diagnostics methods. For instance, as per National Pathology Programme, nearly 800 million tests are being performed annually which is equal to 14 for each person in England and Wales. Additionally, increasing R&D applications of static and dynamic systems is fostering the market growth of digital pathology market.
Global Digital Pathology Market   - Competitive Analysis
The market for digital pathology is characterised by the presence of several well-established and small players, the global market of digital pathology appears to be highly competitive and fragmented. Global players are increasingly expanding their footprint in the emerging nations, making it putting pressure on the regional players, especially in terms of features such as type, product portfolios, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. Well established players are entering into mergers & acquisitions, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.  
Companies like Leica Biosystems; Hamamatsu Photonics, Inc.; and Olympus Corporation are increasingly adopting extensive collaborative strategies to gain more profits and capturing new markets. For instance, in March 2017, Leica Biosystems entered into a strategic partnership with Leeds Hospital to improve productivity and workflow.
Key participants like Royal Philips has acquired the Irish PathXL, one of the largest pathology, image-based analysis firms in order to develop integrated tools targeting applications in computational biology, workflow solutions, education, and image analytics. In addition, these key activities the companies are aiming towards supporting the gradual transition of medical institutions present across the globe from the conventional pathology systems to digital pathology systems.
Thus, we can say that these competitive developments will further enable pathologists to perform high-throughput analysis of clinical image datasets that are diverse in nature and expedite improvement in the diagnosis quality, thereby presenting a potential for adoption new ad improved therapies to enhance patient health outcomes.
microDimensions GmbH (Germany), Mikroscan Technologies, Inc. (U.S.), Q2 Solutions (U.S.), Omnyx, LLC (U.S.), GE Healthcare (UK), Philips Healthcare (U.S.), Huron Digital Pathology Inc. (Canada), ViewsIQ Inc. (Canada), 3DHISTECH Ltd (Hungary) Apollo Enterprise Imaging Corp. (U.S.), Xifin Inc. (U.S.), Definiens (Germany) and others. are some of the prominent players at the forefront of competition in the Global Digital Pathology Market and are profiled in MRFR Analysis. 

Apheresis Market Growth And Restrain Factors Analysis By 2023

Market Scenario
The global apheresis market is presumed to register 10.2 % CAGR during the forecast period (2017-2023), owing to the increasing prevalence of chronic renal diseases, asserts Market Research Future (MRFR). Apheresis is referred to as the procedure of separating and purifying the blood for treating several renal, neurological, autoimmune, hematological, and other diseases. Apheresis involves removal of the blood from the donor or patients and collecting it into an apparatus which separates the component from the blood. The rest of the blood is sent to the patients or the donors. The separation is mainly done using filtration and centrifugation.
Drivers and Constraints Impacting the Market
With the growing prevalence of chronic renal diseases and blood-related diseases, the global apheresis market is considered to stimulate during the estimated period. Increasing complex surgical procedures, rising demand for different component of blood, and growing number of accidents across the globe are considered to augment the market growth in the coming years. Demand for platelets and plasma has also increased which is further impacting the global market positively. Moreover, with continuous advancement in technology and growing need for advanced and automated devices, the market is likely to foster.
On the flip side, high cost of procedures and lack of skilled professionals are some of the major factors considered to impede the market growth in the coming years.
Global Apheresis Market: Segmental Analysis
The global apheresis market has been segmented on the basis of product, procedure, methods, application, end-users, and region.
By mode of product, global apheresis market has been segmented into devices and disposables. The devices segment has been further sub-segmented into platelets separators, plasma separators, and others.
By mode of procedure, the global apheresis market has been segmented into leukapheresis, plateletpheresis, plasmapheresis, erythrocytapheresis, and others.
By mode of methods, the global apheresis market has been segmented into filtration and centrifugation. Among these, centrifugation is further sub-segmented into intermittent flow centrifugation, continuous flow centrifugation, and others.
By mode of application, the global apheresis market has been segmented into oncological diseases, immunological diseases, hematological diseases, cardiovascular diseases, renal diseases, neurological diseases, and others.
By mode of end-users, the global apheresis market has been segmented into hospitals, blood banks, and others.
Regional Insights
Geographically, apheresis market span across regions namely, America, Europe, Asia Pacific, and Rest-of-the-World (RoW).
Among all the regions, America is considered to hold the largest position in the global market and is expected to maintain its dominance during the assessment period. The growth is attributed to the advancement in technology and growing opportunity for apheresis products coupled with the presence of a huge patient population suffering from chronic diseases.
Asia Pacific is considered to be the fastest growing region in the global market owing to the growing demand for blood components for patients. Moreover, rapid development in the healthcare industry along with growing expenditure on health care is considered to contribute to the growth of the global market.
Industry Updates
January 2018: MedAware Systems Inc. has recently launched a comprehensive database on apheresis through its SOHInfo division, carrying data from clinical trials, medical journals, cohort studies, and others.
Competitive Dashboard
The major players operating the global market are Kaneka Corporation (Japan), Terumo BCT Inc. (US), Fresenius Medical Care (Germany), Nikkiso Co. Ltd. (Japan), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Nikkiso Ltd. (Japan), HemaCare Corporation (US), Cerus Corporation (US), Haemonetics Corporation (US), Kawasumi Laboratories Inc. (Japan), Therakos, Inc. (U.S.), and others.

Menstrual Cup Market Pipeline Review, 2019- Identify Key Business Opportunities

Market Scenario
The menstrual cup market is predicted to expand at 3.50 % CAGR over the assessment period (2018-2023 due to the growth in women population, asserts Market Research Future (MRFR). An eco-friendly alternative to tampons and sanitary pads, menstrual cup is derived from medical-grade silicone. It is a female sanitary product that comes in the form of a bell-shaped cup and can be inserted into the vagina during menstruation. Such cups prevent leakage of menstrual fluids which makes it highly convenient.
Browse Sample of the Report @   https://www.marketresearchfuture.com/sample_request/1407 
Drivers and Restraints Impacting the Market
Menstrual cup possess a lifespan ranging from 1-10 years and is one of the most affordable solutions for female hygiene. They are reusable, thus making their demand high. With the growing awareness regarding menstrual cups among the female population, availability of a variety of cups with different sizes, and increasing campaigns conducted by the educational institutes, manufacturers, and the women community are considered some of the major factors propelling the market growth. Government is taking initiatives to educate women about hygiene. Also, the guidelines to use the cup is triggering the product demand in the global market. For example, in 2015, South Africa launched Serithi Campaign which aimed to address the issues faced by young girls the during menstrual cycle.
On the flip side, conservative societies have a low-level acceptance of such products which is expected to retard the market growth in the coming years. Also, tough competition faced from other menstrual product manufacturers can inhibit the market growth.
Global Menstrual Cup Market Segmentation
The market is segmented on the basis of type, product, and distribution channel.
By mode of product, the market is segmented into disposable menstrual cup and reusable menstrual cup. Reusable menstrual cup is presumed to dominate the market during the forecast period. The growth can be attributed to the reusability cycle of these cups which ranges from 1 to 5 years. Moreover, these products are cost-effective and eco-friendly which makes them highly demanding.
By mode of type, the market is segmented into pointy, hollow, flat, and round. Among these, the round menstrual cups account for 43 % of the market share due to the flexible design of such products.
By mode of distribution channel, the market is segmented into retail outlets, online stores, and others. Among these, online store channels account for 62 % of the market share due to penetration of e-commerce stores.
Regional Insights
America is presumed to lead the global menstrual cup market during the assessment period. Programs conducted by the government to create awareness among the consumers is likely to propel the market growth. Also, with the presence of major manufacturers such as LENA Cup and Diva International are likely to propel the market growth.
European is predicted to lead the global market owing to the presence of established players. Also, with the increasing health care cost, the demand for menstrual cup is estimated to trigger in this region.
Asia Pacific is presumed to be the third largest market and registers a steady growth in the healthcare sector. The major contributors are Japan, India, China, the Republic of Korea, and Australia. The market is likely to expand owing to the several awareness programs conducted by the organizations and the government in this region.
Industry News
Loon Labs has created reusable cups which tracks the color and volume of the menstrual fluid. It is the world’s first Bluetooth connected menstrual cup which offers women with analytics and tools to monitor their bodies by using metrics.
Competitive Analysis
As the market continues to propel, it is becoming highly fragmented with the presence of local vendors and established players. The major players operating the global market are Diva International Inc., Vcup, Anigan, Ruby Life Ltd., LadyCup, FemCap Inc., Me Luna, The Keeper Inc., Irisana S.A., and Lunette
Browse for more Report Details @ https://www.marketresearchfuture.com/reports/menstrual-cup-market-1407 

Ureteral Stents Market Segments, Opportunity, Growth And Forecast By End-Use Industry 2019

Ureteral Stents Market Analysis by MRFR expects the market to register 6.6% CAGR during the forecast period of 2019 to 2025, with a market value of USD 302.5 Million in 2018.
A ureteral stent is a thin tube inserted into the ureter to prevent or treat an obstruction of the urine flow from the kidney. The length of the stents used in adult patients varies between 24 and 30 cm.
The global ureteral stents market is driven by factors such as the rising prevalence of kidney diseases and the increasing number of kidney transplants.
Additionally, the technological advancements in ureteral stents and the rising adoption of minimally invasive surgeries are anticipated to fuel the market growth.
For instance, as per the Global Observatory on Donation and Transplantation, in 2016, 89,823 kidney transplants were done globally. Thus, the rising number of kidney transplants fueling the growth of the market.
Moreover, major companies in the market are involved in strategic acquisitions, collaborations, mergers, and new launches to sustain their position in the market.
 For instance, in February 2017, Cook Medical launched Universa, a soft ureteral stent set, in its streamline percutaneous urinary drainage product line. This helped strengthen its ureteral stents product portfolio.
Segmentation
The global ureteral stents market has been segmented based on type, material, treatment, end users, and region.
The global market, based on type, has been bifurcated into double pigtail ureteral stent and others.
The double pigtail ureteral stent segment is expected to hold a significant share of the market due growing use of double pigtail ureteral stents as it provides a safe and effective method of ensuring urinary drainage.
Based on material, the global market is segmented into metallic stents, polymers stents, and others. The polymers stents segment is expected to hold a major share of the market due to growing use of bioabsorbable stents and technological improvement in ureteral stents.
The market, based on treatment, has been divided into kidney stones, kidney transplants, and others.
The kidney stones treatment is expected to hold a major share in the market due to the increasing prevalence of kidney stones. For example, according to Urology Annals, in 2018, worldwide, prevalence of kidney stones is 7% in adults, which will increase with recurrence rate of 30% within ten years. The incidence of kidney stones is growing globally with an estimated prevalence ranging up to 15%. During their lifetime, approximately 7% of women and 13% of men will develop a kidney stone.
Based on end user, the market is segmented into hospitals, nephrological centers, and ambulatory surgical centers. The hospitals segment is expected to hold a major share in the market due availability of facilities for kidney transplant procedures and availability of expertise in the hospital.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The ureteral stents market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European ureteral stents market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
 The ureteral stents market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The ureteral stents market in the Middle East & Africa has been divided into the Middle East and Africa.
Key Players
The Key Players operating in the Global Ureteral Stents Market are Boston Scientific (US), Cook Medical (US), C.R. Bard (US), B. BRAUN (Germany), Olympus (Japan), Coloplast (Denmark), Allium Medical (Israel), Teleflex Incorporated (US), Biomerics (Italy), Medline industries inc. (US), Merit Medical Systems, Inc. (US), and BrightWater Medical (US).